XWAR
CLN
Market cap258mUSD
Oct 09, Last price
18.70PLN
1D
0.11%
1Q
-5.08%
IPO
-40.79%
Name
Celon Pharma SA
Chart & performance
P/E
—
P/S
4.80
EPS
—
Div yield, %
0.43%
Shrs. gr., 5y
3.66%
Rev. gr., 5y
5.91%
Revenues
210m
+18.79%
Net income
-79m
L+130.39%
CFO
24m
P
Dividend
Jun 27, 20240.29762 PLN/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.
Key people
Robert Stanislaw Rzeminski
Chairman of the Supervisory Board
Chairman of the Management Board, Chief Executive Officer
Independent Member of the Supervisory Board · since 2018
Michal Krzysztof Kowalczewski
Independent Member of the Supervisory Board
Urszula Wieczorek
Member of the Supervisory Board
Artur Wieczorek
Member of the Supervisory Board
Legal address
KIEŁPIN OGRODOWA 2A
KIEŁPIN, 14 05-092
PL
KIEŁPIN, 14 05-092
PL
Headquarters
KAZUŃ NOWY MARYMONCKA 15
KAZUŃ NOWY, 14 05-152
PL
KAZUŃ NOWY, 14 05-152
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||